Kineta, Inc. (KANT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kineta, Inc. (KANT) has a cash flow conversion efficiency ratio of 0.153x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.22 Million) by net assets ($-7.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Kineta, Inc. for the company's overall valuation and market capitalisation.
Kineta, Inc. - Cash Flow Conversion Efficiency Trend (2020–2023)
This chart illustrates how Kineta, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Kineta, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kineta, Inc. ranked by their cash flow conversion efficiency. Explore Kineta, Inc. cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Datasea Inc
NASDAQ:DTSS
|
0.191x |
|
Addex Therapeutics Ltd
NASDAQ:ADXN
|
-0.233x |
|
Smart Powerr Corp
NASDAQ:CREG
|
0.017x |
|
Aston Martin Lagonda Global Holdings PLC
LSE:AML
|
-0.397x |
|
Socket Mobile Inc
NASDAQ:SCKT
|
0.057x |
|
Power Line Engineering Public Company Limited
BK:PLE
|
0.243x |
|
LDC Dental Public Company Limited
BK:LDC
|
0.022x |
|
Trinitan Metals and Minerals
JK:PURE
|
0.047x |
Annual Cash Flow Conversion Efficiency for Kineta, Inc. (2020–2023)
The table below shows the annual cash flow conversion efficiency of Kineta, Inc. from 2020 to 2023. View today's stock price for Kineta, Inc. for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $3.06 Million | $-16.21 Million | -5.299x | -27.26% |
| 2022-12-31 | $4.57 Million | $-19.03 Million | -4.164x | -378.69% |
| 2021-12-31 | $-11.95 Million | $-17.85 Million | 1.494x | +1502.09% |
| 2020-12-31 | $-21.55 Million | $2.30 Million | -0.107x | -- |
About Kineta, Inc.
Kineta, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies that transform patients' lives in the United States. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combinati… Read more